Skip to main content
Clinical Trials/NL-OMON48989
NL-OMON48989RecruitingNot Applicable

A feasibility study on Cerenkov Luminescence Imaging using Gallium-68 PSMA during prostate cancer surgery - CLIPPS-Cerenkov Luminescence Imaging during Prostate cancer Surgery

Antoni van Leeuwenhoek Ziekenhuis0 sites30 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
30

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational invasive

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • - Primary prostate cancer >18 year, eligible for PSMA PET scan (PSA>=20 ng/mL
  • or >=cT3 or Gleason>=7)
  • - Tumour larger than 2cm on MRI.
  • - Signed informed consent
  • - Voluntary understanding
  • - Scheduled for radical prostatectomy surgery
  • - PSMA uptake on pre-operative 68Ga-PSMA PET scan

Exclusion Criteria

  • - Usage of Indocyanine green (ICG) during surgery
  • - No PSMA uptake on clinical PET/CT-scan
  • - Subjects who have an existing medical condition that would compromise their
  • participation in the study

Investigators

Sponsor
Antoni van Leeuwenhoek Ziekenhuis

Similar Trials